GGrantIndex
Sort

50,496 grants matching lung cancer

Enhanced treatment of breast cancer via biodegradable polymer nanoparticles

$391,826
David Peter Cormode · University Of Pennsylvania · R21 · FY2025 · CA

Role of GATA3 in transcriptional pathways suppressing breast cancer metastasis

$391,822
Zena Werb · University Of California, San Francisco · R01 · FY2019 · CA

Discovery of Chemical Probes and Therapeutic Leads, Phase II

$391,800
Joseph M Fox · University Of Delaware · P20 · FY2021 · GM

Novel bisphosphonates for multiple myeloma therapy

$391,786
Alexander Karpeisky · Mbc Pharma, Inc. · R44 · FY2008 · CA

(PQ5) Mitochondria are endocellular symbionts that serve as targets for immune recognition

$391,766
Andrea Facciabene · University Of Pennsylvania · R01 · FY2019 · CA

ANTITUMOR PROPERTIES OF DISCODERMOLIDE AND DERIVATIVES

$391,761
Harbor Branch Oceanographic Inst, Inc. · R01 · FY2000 · CA

Noninvasive detection of circulating RNAs for lung cancer early detection and prognosis

$391,724
Yun Wu · State University Of New York At Buffalo · R33 · FY2017 · CA

Multiplexed nanoparticle delivery to increase CRISPR/Cas gene editing for enhanced cancer therapy

$391,721
Daniel John Siegwart · Ut Southwestern Medical Center · R01 · FY2025 · CA

Multiplexed nanoparticle delivery to increase CRISPR/Cas gene editing for enhanced cancer therapy

$391,721
Daniel John Siegwart · Ut Southwestern Medical Center · R01 · FY2022 · CA

Defining the Critical Function and Regulation of NNMT in Breast Cancer Progression and Metastasis

$391,709
Binhua P Zhou · University Of Kentucky · R01 · FY2025 · CA

Establishing the clinical utility of cell-free tumor DNA methylation profiling as a reliable liquid biopsy approach in brain tumors

$391,675
Gelareh Zadeh · University Health Network · R01 · FY2025 · CA

ApoVax104-TB as a Novel Vaccine for Tuberculosis

$391,672
Kathryn J. Macleod · Apovax, Inc. · R43 · FY2008 · AI

Targeting epithelial membrane protein 2 (EMP2) in retinopathy of prematurity

$391,647
Alison Chu · University Of California Los Angeles · R01 · FY2025 · EY

Targeting epithelial membrane protein 2 (EMP2) in retinopathy of prematurity

$391,647
Alison Chu · University Of California Los Angeles · R01 · FY2024 · EY

Targeting epithelial membrane protein 2 (EMP2) in retinopathy of prematurity

$391,647
Alison Chu · University Of California Los Angeles · R01 · FY2023 · EY

Regulation and Targeting of CD24 in Bladder Cancer

$391,637
Dan Theodorescu · Cedars-Sinai Medical Center · R01 · FY2019 · CA

PROMINENT - IARC

$391,529
Paul Joseph Brennan · International Agency For Res On Cancer · OT2 · FY2022 · CA

Preventing Melanoma Metastasis by Targeting Lipid Vulnerabilities in Lymph

$391,523
Jessalyn Ubellacker · Harvard University D/B/A Harvard School Of Public Health · R01 · FY2025 · CA

Comparative Effectiveness of Surgical Treatments for Lung Cancer in the Elderly

$391,520
Juan P Wisnivesky · Icahn School Of Medicine At Mount Sinai · R01 · FY2011 · HS

Cancer Care and Outcomes for Disabled Medicare Patients

$391,517
Beth Israel Deaconess Medical Center · R01 · FY2003 · CA

DNA Methylation Marks of COPD

$391,515
Edwin K Silverman · Brigham And Women'S Hospital · P01 · FY2015 · HL

Ancillary T Cell Based Studies in SPIROMICS

$391,478
Farrah Kheradmand · Baylor College Of Medicine · R01 · FY2015 · HL

Rapid, simple, and ultrasensitive quantitation of KRAS ctDNA at the point of care using CRISPR/Cas amplification and digital resolution biosensor microscopy

$391,467
Brian T. Cunningham · University Of Illinois At Urbana-Champaign · R33 · FY2023 · CA

Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic target

$391,466
Cyrus Vaziri · Univ Of North Carolina Chapel Hill · R01 · FY2023 · CA

Statistical Methods and Validation Analyses for the Integration of External Data in Clinical Trials

$391,445
Lorenzo Trippa · Dana-Farber Cancer Inst · R01 · FY2021 · LM